Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Short term Debt (2022 - 2024)

Inmune Bio's Short term Debt history spans 3 years, with the latest figure at $2.5 million for Q3 2024.

  • For Q3 2024, Short term Debt fell 75.06% year-over-year to $2.5 million; the TTM value through Sep 2024 reached $2.5 million, down 75.06%, while the annual FY2023 figure was $9.9 million, 98.42% up from the prior year.
  • Short term Debt for Q3 2024 was $2.5 million at Inmune Bio, down from $5.0 million in the prior quarter.
  • Across five years, Short term Debt topped out at $10.0 million in Q3 2023 and bottomed at $2.5 million in Q3 2024.
  • The 3-year median for Short term Debt is $6.2 million (2022), against an average of $6.2 million.
  • The largest annual shift saw Short term Debt surged 300.0% in 2023 before it tumbled 75.06% in 2024.
  • A 3-year view of Short term Debt shows it stood at $5.0 million in 2022, then skyrocketed by 98.42% to $9.9 million in 2023, then tumbled by 74.86% to $2.5 million in 2024.
  • Per Business Quant, the three most recent readings for INMB's Short term Debt are $2.5 million (Q3 2024), $5.0 million (Q2 2024), and $7.5 million (Q1 2024).